TNFSF11 and aortic stenosis: [22] Calcific aortic stenosis, like osteoporosis, is a disease associated with aging and inflammation. [23] A therapeutic strategy designed to antagonize the effect of increased RANKL signaling upon tissue inflammation and mineralization, using the neutralizing monoclonal antibody denosumab, is safe and effective for patients with osteoporosis. [24] Thus, an approach with a similar mechanistic basis targeted at pathological dysregulation of mineralization in aortic valve tissue may offer opportunities for exploration of therapies for patients who are prone to develop aortic stenosis.